Account wins

Share this article:

MedAccess, a division of Access Communications, has been named agency of record for Stiefel Laboratories, brought on board to help with the launch of skin-care products, Extina and RevalèSkin. Extina was recently FDA approved for the topical treatment of seborrheric dermatitis, a chronic, recurrent skin condition that affects about five percent of the country's population. Extina is administered via VersaFoam HF, which studies show offers consistent skin permeation, drug distribution and drug delivery. This easy-to-use drug also absorbs quickly and is non-drying with no residue. RevalèSkin is the first and only professional anti-aging skin care line formulated with 1% CoffeeBerry, a natural super-antioxidant.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.